Alleged breaches of "standards of medical care" in a patient overdose death possibly related to chronic opioid analgesic therapy, application of the controlled substances model guidelines: Case report

Pain Medicine

Volumn 10, Issue 3, 2009, Pages 565-572

  Fishbain, David A ^a,c   Lewis, John E ^a   Gao, Jinrun ^d   Cole, Brandly ^b   Rosomoff, Rennée Steele ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Rosomoff   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d State Farm Insurance   (United States)

Author keywords

Breaches of standards; Chronic opioid analgesic therapy; Chronic pain; Daubert case; Death; Federal state medical board model guidelines; Federation of state medical board model policy; Informed consent; Intractable pain; Medical expert; Medicolegal; Opioids; Overdose; Standards of medical care

Indexed keywords

ANTIINFLAMMATORY AGENT; DIAZEPAM; DOXEPIN; HYDROCODONE; METHADONE; MORPHINE; NORDAZEPAM; OPIATE; OXYCODONE; TEMAZEPAM;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED DRUG RELEASE; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ELECTROSTIMULATION; EVENING DOSAGE; FEMALE; FORENSIC TOXICOLOGY; FUNCTIONAL ASSESSMENT; HEALTH CARE ACCESS; HUMAN; MALPRACTICE; MEDICAL INFORMATION; MEDICAL RECORD; MEDICOLEGAL ASPECT; MENTAL HEALTH CARE; MORNING DOSAGE; MUSCLE STRAIN; NEGLIGENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PHYSIOTHERAPY; RANGE OF MOTION; SCHIZOPHRENIA; SHOULDER PAIN; TREATMENT DURATION;

ADULT; ANALGESICS, OPIOID; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DIAZEPAM; DOXEPIN; FEMALE; HEROIN DEPENDENCE; HUMANS; HYDROCODONE; MALPRACTICE; METHADONE; NORDAZEPAM; OVERDOSE; PAIN; PAIN MEASUREMENT; PRACTICE GUIDELINES AS TOPIC; SHOULDER; TEMAZEPAM;

EID: 65349093433     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2008.00523.x     Document Type: Article

References (20)

1. Fishbain DA. Chronic pain and addiction. In: Boswell MV, Cole BE, eds. Werner's Pain Management. A Practical Guide for Clinicians, 7th edition. Boca Raton, FL: American Academy of Pain Medicine CRS, Taylor and Francis; 2006: Chapter 10, 117-39.
2. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ 2006;174(11):1589-94.
3. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293(24):3043-52.
4. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, nonmalignant pain. Curr Med Res Opin 2005;21(10):1555-68.
5. Fishbain DA, Cutler RB, Cole B, et al. Medico-legal rounds: Medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: A case report. Pain Med 2003;4(2):195-201.
6. Fishbain DA. Medico-legal rounds: Medico-legal issues and alleged breaches of "standards of medical care" in opioid tapering for alleged opioid addiction. Pain Med 2002;3(2):135-42.
7. Fishbain DA, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Medico-legal rounds: Medico-legal issues and alleged breaches of "standards of medical care" in a patient motor vehicle accident, allegedly related to chronic opioid analgesic therapy; case report. J Opioid Manag 2007;3(1):16-20.
8. The Use of Opioids for the Treatment of Chronic Pain: A Consensus Statement from the American Academy of Pain Medicine (AAPM) and the American Pain Society (APS). Glenview, IL: AAPM and APS; 1997.
9. Federation of State Medical Boards of the United States, Inc. Model Guidelines for the use of Controlled Substances for the Treatment of Pain. Dallas, TX: Federation of State Medical Boards; 1998.
10. Portenoy RK. Opioid therapy for chronic nonmalignant pain: Current status. In: Fields HL, Lieberkind JC, eds. Progress in Pain Research and Management, Vol. 1, Pharmacological approaches to the treatment of chronic pain: New concepts and critical issues. Seattle, WA: IASP Press; 1994:39-45.
11. Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. 2004. Available at: http://www.fsmb.org/pdf/ 2004_grpol_Controlled_Substances.pdf (accessed October 6, 2008).
12. Law of Florida 64B8-9.013 standards for the use of controlled substances for the treatment of pain. 10/19/03. Available at: https://www.flrules.org/gateway/chapterhome.asp?Chapter=64B8-9 (accessed October 6, 2008).
13. Keskinbora K, Pekel AF, Aydiali I. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic pain. J Pain Symptom Manage 2007;34(2):183-9.
14. Passik SD, Kirsh K, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004;26(4):552-61.
15. Gatchel RJ, Polatin P, Deschner R, Nue C, Noor G. Screening for problematic prescription opioid use. Clin J Pain 2001;17:220-8.
16. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Steele-Rosomoff R. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9(4):444-59.
17. Rich BA. Medico-legal commentary on Fishbain DA, et al. Pain Med 2003;4(2):202-5.
18. Chambler v. McClured. 505F 2d 489 (6th Cir. 1974).
19. Daubert v. Merrell Dow Pharmaceutical, Inc. 509U S 579, 113S. Ct. 2786,125 L.Ed. 2d 469 (U.S. Cal Jun 28, 1993).
20. Fishman SM. Responsible Opioid Prescribing. A Physician Guide. Dallas, TX: Federation of State Medical Boards; 2007.